Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care ...
Jun 15, 2026
0
4
The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations ...
May 29, 2026
0
8
Treating breast cancer that has begun to spread around the body with targeted radiotherapy could help patients to live longer without their cancer getting worse, according to the results of a small randomized controlled trial ...
May 17, 2026
0
17
An international group of experts led by the Comprehensive Cancer Center (CCC) at MedUni Vienna and University Hospital Vienna has established endpoints for clinical trials in patients with cancer and isolated metastases. ...
Apr 28, 2026
0
5
Before her cancer diagnosis in early 2017, 48-year-old Caitlin Delaney, who is based in Australia, had been struggling with a troubling mix of symptoms comprising extreme fatigue, chronic sinusitis, and appetite changes including ...
Apr 23, 2026
0
4
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B-cell lymphoma patients than the widely used International Prognostic Index. By identifying patients ...
Apr 22, 2026
0
1
Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate noninferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression-free survival (PFS) ...
Apr 13, 2026
0
3
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma ...
Mar 4, 2026
0
6
Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international ...
Mar 2, 2026
0
10
A study by investigators from Mass General Brigham Cancer Institute evaluates the efficacy and safety of proton therapy for patients with lower grade gliomas (LGGs). The single-arm prospective phase 2 trial results demonstrated ...
Feb 11, 2026
0
10
